English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Because of the lack of an appropriate antibody against the canine CD25 molecule, we investigated whether anti-human CD25 antibody, ACT-1, could be useful in detecting canine T-lymphocyte proliferation. Peripheral mononuclear cells from a dog were cultured for 4 days with or without concanavalin A stimulation. In the last 24 hr, bromodeoxyuridine (BrdU) and human recombinant IL-2 were added. While the cell cycle was detected using anti-BrdU antibody and 7-amino-actinomycine (7-AAD), the cultured cells were stained with anti-canine CD4 antibody and ACT-1. The results showed that T-lymphocytes reactive to ACT-1 were present in the G2/M and G0/G1 phases in 94.4% and 70.0% of CD4-positive T-lymphocytes, respectively, suggesting that flow cytometory with ACT-1 might be useful in detecting canine T-lymphocytes during and after activation.

The Antibody against Human CD25, ACT-1, Recognizes Canine T-lymphocytes in the G2/M and G0/G1 Phases of the Cell Cycle during Proliferation